A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

芬戈莫德 医学 多发性硬化 安慰剂 磁共振成像 内科学 干扰素β-1a 口服 药理学 肿瘤科 免疫学 病理 放射科 干扰素β 替代医学
作者
Ludwig Kappos,Ernst Wilhelm Radue,Paul W O'Connor,Chris H. Polman,Reinhard Hohlfeld,Peter A. Calabresi,Krzysztof W. Selmaj,Catherine Agoropoulou,Małgorzata Leyk,Lixin Zhang-Auberson,Pascale Burtin
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:362 (5): 387-401 被引量:2895
标识
DOI:10.1056/nejmoa0909494
摘要

BACKGROUND: Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 studies of multiple sclerosis. METHODS: In our 24-month, double-blind, randomized study, we enrolled patients who had relapsing-remitting multiple sclerosis, were 18 to 55 years of age, had a score of 0 to 5.5 on the Expanded Disability Status Scale (which ranges from 0 to 10, with higher scores indicating greater disability), and had had one or more relapses in the previous year or two or more in the previous 2 years. Patients received oral fingolimod at a dose of 0.5 mg or 1.25 mg daily or placebo. End points included the annualized relapse rate (the primary end point) and the time to disability progression (a secondary end point). RESULTS: A total of 1033 of the 1272 patients (81.2%) completed the study. The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo). Fingolimod at doses of 0.5 mg and 1.25 mg significantly reduced the risk of disability progression over the 24-month period (hazard ratio, 0.70 and 0.68, respectively; P=0.02 vs. placebo, for both comparisons). The cumulative probability of disability progression (confirmed after 3 months) was 17.7% with 0.5 mg of fingolimod, 16.6% with 1.25 mg of fingolimod, and 24.1% with placebo. Both fingolimod doses were superior to placebo with regard to MRI-related measures (number of new or enlarged lesions on T(2)-weighted images, gadolinium-enhancing lesions, and brain-volume loss; P<0.001 for all comparisons at 24 months). Causes of study discontinuation and adverse events related to fingolimod included bradycardia and atrioventricular conduction block at the time of fingolimod initiation, macular edema, elevated liver-enzyme levels, and mild hypertension. CONCLUSIONS: As compared with placebo, both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI. These benefits will need to be weighed against possible long-term risks. (ClinicalTrials.gov number, NCT00289978.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
外向的大米完成签到,获得积分10
1秒前
酷波er的应助被yjt采纳,获得10
1秒前
邱邱科研发布了新的文献求助10
1秒前
18859805972完成签到 ,获得积分10
2秒前
2秒前
如初发布了新的文献求助10
3秒前
过度干涉完成签到 ,获得积分10
3秒前
haocong完成签到 ,获得积分10
3秒前
搜集达人的应助被什玖采纳,获得10
4秒前
5秒前
无极微光的应助被念安采纳,获得20
5秒前
嘻嘻完成签到,获得积分10
6秒前
苍耳完成签到,获得积分10
6秒前
6秒前
linjunqi完成签到,获得积分10
6秒前
Alien完成签到 ,获得积分10
6秒前
6秒前
6秒前
ding的应助被Twinkle采纳,获得10
7秒前
Akim的应助被Run采纳,获得10
7秒前
把糖还我完成签到,获得积分10
7秒前
oyyh完成签到,获得积分20
7秒前
碎月发布了新的文献求助10
7秒前
法则房子完成签到,获得积分10
7秒前
8秒前
大奎完成签到,获得积分10
8秒前
852的应助被Li采纳,获得10
8秒前
10秒前
10秒前
10秒前
九陌完成签到,获得积分10
10秒前
殷勤的紫槐的应助被xfy采纳,获得200
11秒前
Linkkk发布了新的文献求助10
11秒前
11秒前
shenkekeshen的应助被曲书文采纳,获得10
12秒前
13秒前
13秒前
初景发布了新的文献求助10
13秒前
yjt发布了新的文献求助10
13秒前
WM发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189431
求助须知:如何正确求助?哪些是违规求助? 9576755
关于积分的说明 21849578
捐赠科研通 7787361
什么是DOI,文献DOI怎么找? 3435577
关于科研通互助平台的介绍 2559772
邀请新用户注册赠送积分活动 2482529